Proteolytic cell surface release ('shedding') of the prion protein (PrP), a broadly expressed
GPI-anchored glycoprotein, by the metalloprotease ADAM10 impacts on neurodegenerative …

Aqueously soluble oligomers of amyloid-β peptide may be the principal neurotoxic forms of
amyloid-β in Alzheimer's disease, initiating downstream events that include tau …

ABSTRACT The recent Research Framework proposed by the US National Institute on
Aging and the Alzheimer's Association (NIA-AA) recommends that Alzheimer's disease be …

A recent study demonstrated a substantial signal increase when employing a 0.5% acetic
acid buffer additive instead of the traditional 0.1% formic acid used in shotgun proteomics. In …

Non‐invasive sensory stimulation in the range of the brain's gamma rhythm (30–100 Hz) is
emerging as a new potential therapeutic strategy for the treatment of Alzheimer's disease …

Amyloid-β (Aβ) oligomers are a cause of neurodegeneration in Alzheimer's disease (AD).
These soluble aggregates of the Aβ peptide have proven difficult to study due to their …

Alzheimer's disease (AD) is the most prevalent neurodegenerative condition. The definitive
diagnosis of AD remains a post-mortem neuropathological study of the brain. Unfortunately …

Alzheimer’s disease linked Aβ42 exerts product feedback inhibition on γ-secretase
impairing downstream cell signaling - PMC Back to Top Skip to main content NIH NLM Logo …

Oligomers formed from monomers of the amyloid β-protein (Aβ) are thought to be central to
the pathogenesis of Alzheimer's disease (AD). Unsurprisingly for a complex disease, current …

Abstract Background The prion protein (PrP) is known to bind certain soluble aggregates of
the amyloid β-protein (Aβ), and two regions of PrP, one centered around residues 19–33 …